Additional Listing and Total

RNS Number : 1946U

Immupharma PLC

11 October 2010

 



11 October 2010

Immupharma plc

ADDITIONAL LISTING AND TOTAL VOTING RIGHTS

PICTET INCREASE HOLDING TO OVER 3%

ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company"), the specialist discovery and development pharmaceutical company announces that following the exercise of options held by the liquidators to Dawnay Day Corporate Finance Limited, application has been made to the London Stock Exchange for the admission of 441,000 new ordinary shares of 10 pence each in the Company to trading on AIM.  It is expected that these new ordinary shares, which will rank pari passu with the existing ordinary shares of the Company, will be admitted to trading on 12 October 2010.

Following the allotment of the new ordinary shares, the Company's issued share capital will consist of 81,532,463 Ordinary Shares of 10p each which entitle the holder to one vote per share.  Therefore, the total number of voting rights is 81,532,463.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules.

The Company is also pleased to announce that Pictet Overseas Trust Corporation Limited have increased their stake in Immupharma to 3.02%. 

Commenting on the developments, Chairman, Richard Warr, said:

"We are delighted that Pictet have increased their shareholding in ImmuPharma in excess of 3% and are pleased to have the continued support of such a prestigious Swiss bank."

For further information, please contact:

ImmuPharma PLC:

Dimitri Dimitriou, Chief Executive Officer                                       [phone]

Richard Warr, Chairman                                                

Tracy Weimar, VP, Operations                                                   

Buchanan Communications

Lisa Baderoon, Mark Court                                                         [phone]

Panmure, Gordon & Co., NOMAD & Broker

Andrew Burnett                                                                          [phone]

Rakesh Sharma                                                            

Execution Noble & Co, Joint Broker

James Bromhead                                                                       [phone]

Richard Crawley

 

END

 

 

LISBXBDGDGBBGGB